22 February, 2017

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

Sitryx Reports Positive Phase 1b Results for First-in-Class Oral PKM2 Modulator SYX-5219 in Patients with Moderate to Severe Atopic Dermatitis

GenSight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa

Sensorion Announces the Appointment of Louis J. Arcudi III as Chief Financial Officer

GenSight Biologics Reports Cash Position as of September 30, 2026

Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)

Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide